Peter Reitano, CEO of Gwella, speaks to Psychedelic Health about the company’s mission to provide education on psychedelics and raise acceptance of the compounds beyond mental...
Incannex Healthcare has confirmed that its PsiGAD1 clinical trial has achieved its interim milestone of 29 patients completing primary endpoint assessments.
A social poll by the healthy living and aging platform, Goldster, revealed that over 65s are more open to trying microdosing than those under the age...
Algernon Pharmaceuticals has announced that its subsidiary, Algernon NeuroScience (AGN Neuro), has dosed the first subject in its Phase 1 clinical study of an intravenous formulation...
Psychedelics are being touted as a potential breakthrough in the area of mental health treatment.
Field Trip Health & Wellness has launched Field Trip Online Therapy for people seeking therapeutic support and for people looking to integrate insights and learnings from...
Irwin Naturals has signed a Letter of Intent entering into a partnership with Braxia Scientific – which is developing innovative ketamine and psilocybin treatments for mental...
Reunion Neuroscience has completed the interim data analysis for its Phase 1 clinical trial with lead asset RE104, a unique 4-OH-DiPT prodrug.
The first patient has been dosed in Small Pharma’s Phase I study that is comparing the profiles of the company’s proprietary formulation of DMT.
A global ayahuasca survey has found 70% experience physical and 55% mental health adverse effects, but only 2.3% of participants reporting physical adverse events required medical...